Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide

  • Int J Cardiol. 2019 Apr 15;281:166-171. doi: 10.1016/j.ijcard.2018.06.002.
Tomoko Ichiki  1 ,  Nina Dzhoyashvili  1 ,  John C Burnett Jr  2
Affiliations
  • 1. Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, Department of Physiology and Bioengineering, College of Medicine Mayo Clinic, Rochester, MN, USA.
  • 2. Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, Department of Physiology and Bioengineering, College of Medicine Mayo Clinic, Rochester, MN, USA. Electronic address: [email protected].
PMID: 29941213 DOI: 10.1016/j.ijcard.2018.06.002
Abstract

Cenderitide is a novel designer natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to co-activate the two NP receptors, particulate guanylyl cyclase (pGC)-A and pGC-B. The rationale for its design was to achieve the renal-enhancing and anti-fibrotic properties of dual receptor activation, but without clinically significant hypotension. Here, we review the biology of the NPs and the rationale for their use in heart failure. Most importantly, we present the key studies related to the discovery of Cenderitide. Finally, we review the key clinical studies that have advanced this first-in-class dual NP receptor activator for heart failure.

Keywords
Designer natriuretic peptide; Drug development; Heart failure; Natriuretic peptide; Receptors.
Products